NCT03715595 (T2TRAonSSDM) is a NA clinical trial of SSDM group in Rheumatoid Arthritis, sponsored by Peking University People's Hospital.

Who is sponsoring NCT03715595?

NCT03715595 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT03715595?

Interventions in NCT03715595: SSDM group.

What condition does NCT03715595 study?

NCT03715595 studies Rheumatoid Arthritis.

Is NCT03715595 still recruiting?

NCT03715595 is currently status unknown. Last updated 5 June 2020.

Last reviewed 2020-06-05 · How we verify

NCT03715595: T2TRAonSSDM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Treat-to-target Study of RA Based on Smart System of Disease Management(SSDM)

Status unknown NA Last updated 5 June 2020

What this trial tests

NA trial testing SSDM group in Rheumatoid Arthritis in 2,200 participants. Status unknown.

Timeline

1 November 2018

Primary endpoint
29 May 2020

29 June 2020

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	2,200
Start date	1 November 2018
Primary completion	29 May 2020
Estimated completion	29 June 2020
Sites	1 location across China

Drugs / interventions tested

SSDM group

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Peking University People's Hospital

Who can join

18 and older, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluate the Smart System of Disease Management（SSDM）to improve the treat-to-target(T2T) and the safety of drug in the treatment of rheumatoid(RA). All participants will be randomized in the SSDM group and the control group. The patients in the SSDM group will use the SSDM every month and the control group will receive the conventional therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Management of Rheumatoid Arthritis With a Digital Health Application: A Multicenter, Pragmatic Randomized Clinical Trial.
Li C, Huang J, Wu H, Li F, et al · · 2023 · cited 26× · PMID 37058302 · DOI 10.1001/jamanetworkopen.2023.8343

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03715595 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 5 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03715595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing